# Effect of Adding Vildagliptin vs Glimepiride to Metformin on Inflammation's Markers in Type-2 Diabetic Patients With CAD

> **NCT03693560** · PHASE4 · COMPLETED · sponsor: **Damanhour University** · enrollment: 80 (actual)

## Conditions studied

- Coronary Artery Disease
- Diabetes Mellitus, Type 2

## Interventions

- **DRUG:** Vildagliptin 50 mg Oral Tablet
- **DRUG:** Metformin 1000 mg Oral Tablet
- **DRUG:** Glimepiride upto 4 mg Oral Tablet

## Key facts

- **NCT ID:** NCT03693560
- **Lead sponsor:** Damanhour University
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-10-08
- **Primary completion:** 2019-09-10
- **Final completion:** 2019-10-10
- **Target enrollment:** 80 (ACTUAL)
- **Last updated:** 2023-06-13

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03693560

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03693560, "Effect of Adding Vildagliptin vs Glimepiride to Metformin on Inflammation's Markers in Type-2 Diabetic Patients With CAD". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03693560. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*